Serum cytokine profile of laryngeal squamous cell carcinoma patients

Sotirović, Jelena; Perić, Aneta; Vojvodić, Danilo; Baletić, Nenad; Zaletel, Ivan; Stanojević, Ivan; Erdoglija, Milan; Milojević, Milanko

doi:10.1017/s0022215117000573

Cited by 13 publications

(14 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our observation showing that exacerbated NOS2 expression associated with tumor necrosis (data not shown) reinforces that interpretation. Considering recent reports, we speculate that the synthesis of NO and IL-10 by tumor-infiltrating macrophages and Tregs [32, 37, 38] would constitute the ground to the inhibition of a protective Th1 response and the condition to the development of IL-10-associated LSCC's loco-regional metastases risk [36, 39]. In turn, in these conditions, coexpression of IL-6 would increase the risk of lymph node metastases by eliciting MDSCs activity and suppressing cytotoxic T-cell function [40, 41].…”

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

Expression Analysis of the Mediators of Epithelial to Mesenchymal Transition and Early Risk Assessment of Therapeutic Failure in Laryngeal Carcinoma

Kariche

Moulaï²,

Sellam

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

Laryngeal squamous cell carcinoma (LSCC) is an aggressive malignancy which lacks early predictors of prognosis. Here, we hypothesized that expression and prognostic characterization of the critical mediators of epithelial to mesenchymal transition (EMT) may provide key information in this regard. Linear regression and multiple correspondence analyses were performed on immunohistochemical data obtained from 20 invasive tumors. Principal component and unsupervised hierarchical clustering were used to analyze the dataset patterns associating with LSCC metastatic profile. Survival and death risk assessments were performed using Kaplan–Meier and hazard ratio tests. Data mining analysis using CHAID decision tree and logistic regression analysis was applied to define the predictive value of the risk factors of tumor aggressiveness. Our analyses showed, that in invasive LSCC tumors, cells associating with a mesenchymal profile were likely to exhibit enhanced NOS2, TGF-β, and IL-17A expression levels, concomitantly to NF-κB nuclear translocation. IHC data deciphering determined that EMT induction was also linked to the enrichment of the tumors with CD68+ populations and IL-10 signal. Strikingly, dataset cluster analysis showed that these signatures could define distinct patterns of invasive tumors, where NOS2 associated with IL-10 expression, and TGF-β and IL-17A signals associated with MMP-9 activation. Decision tree analysis identified IL-17A as a possible predictor of LSCC aggressiveness. Altogether, our results show that distinct immunological patterns would support the acquisition of EMT features in invasive LSCC and suggest that IL-17A may be useful in the early identification of patients “at-risk” of therapeutic failure.

show abstract

Section: Discussionmentioning

confidence: 83%

“…Considering the reports describing IL-10 upregulation in LSCC and its potential role in EMT induction in cancer [32, 33], we next hypothesized that the cytokine could, in the context of EMT induction in LSCC, be of importance. As described by others, we observed that IL-10 was increased at the systemic level (Figure 4(a)).…”

Section: Resultsmentioning

confidence: 99%

Expression Analysis of the Mediators of Epithelial to Mesenchymal Transition and Early Risk Assessment of Therapeutic Failure in Laryngeal Carcinoma

Kariche

Moulaï²,

Sellam

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…The levels of these factors in the aqueous humor samples were within the detection ranges of the assays, with the minimum detectable concentration being 0.64 pg/mL for VEGF, 0.37 pg/mL for PlGF, 0.03 ng/mL for DOI: 10.1159/000488494 sICAM-1, 1.2 pg/mL for MCP-1, 0.64 pg/mL for PDGF-AA, 0.29 pg/mL for IL-6, 0.14 pg/mL for IL-8, 0.14 pg/mL for IL-12(p70), and 0.12 pg/mL for IL-13. The normal mean serum levels of these cytokines were as follows: 94.6 pg/mL for VEGF, 14.0 pg/ mL for PlGF, 8.07 ng/mL for sICAM-1, 154 pg/mL for MCP-1, 1.77 ng/mL for PDGF-AA, 4.06 pg/mL for IL-6, 36.1 pg/mL for IL-8, 259 pg/mL for IL-12(p70), and 104 pg/mL for IL-13 [8][9][10][11][12]. In addition, the molecular weights were 20 kDa for VEGF, 24 kDa for PlGF, 74 kDa for sICAM-1, 11 kDa for MCP-1, 28 kDa for PDGF-AA, 23 kDa for IL-6, 11 kDa for IL-8, 75 kDa for IL-12(p70), and 15 kDa for IL-13.…”

Section: Measurement Of Cytokines and Growth Factorsmentioning

confidence: 99%

Comparing Cytokine Kinetics between Ranibizumab and Aflibercept in Central Retinal Vein Occlusion with Macular Edema

et al. 2018

View full text Add to dashboard Cite

Purpose: To investigate dynamic changes in aqueous humor levels of vascular endothelial growth factor (VEGF), placental growth factor (PlGF), and inflammatory factors in patients receiving intravitreal ranibizumab injection (IRI) or intravitreal aflibercept injection (IAI) to treat central retinal vein occlusion (CRVO) with macular edema. Methods: In 22 CRVO patients scheduled to receive 3 doses of ranibizumab (11 eyes) or aflibercept (11 eyes) at monthly intervals, aqueous samples were collected at the time of intravitreal injection. The concentrations of VEGF, PlGF, soluble intercellular adhesion molecule-1, monocyte chemotactic protein (MCP)-1 (CCL2), platelet-derived growth factor-AA, interleukin (IL)-6, IL-8 (CXCL8), IL-12(p70) (IL12B), and IL-13 in aqueous samples were measured by the suspension array method. Results: Visual acuity and foveal thickness improved significantly in both the IRI group and the IAI group. In addition, aqueous levels of VEGF and PlGF as well as MCP-1 and IL-6 decreased significantly over time in both groups. These parameters did not significantly differ between both groups. Conclusions: In CRVO patients, both ranibizumab and aflibercept achieved similar improvement in clinical parameters and similar reductions in aqueous VEGF, PlGF, MCP-1, and IL-6 levels.

show abstract

“…It was recently reported that cisplatin in vitro at lower doses enhances antigen presentation and T-cell killing (32). Panels of cytokines have been studied in other groups of patients with a malignant disease but not up to 1 year after termination of treatment (20, 22, 25, 33, 34).…”

Section: Discussionmentioning

confidence: 99%

Systemic Inflammatory Reaction in Patients With Head and Neck Cancer—An Explorative Study

et al. 2019

View full text Add to dashboard Cite

Aim: To assess the longitudinal pattern of pro-inflammatory cytokines and growth factors in serum up to 1 year following treatment for head and neck cancer.Materials and Methods: Patients with newly diagnosed, curable head and neck cancer were included (n = 30). The most common subsite was oropharynx (n = 13) followed by oral cavity (n = 9). Blood was drawn from all patients at regular intervals (before treatment, 7 weeks after the start of the treatment, and at 3 months and 1 year after termination of treatment) and analyzed for cytokines (Il-1β, Il-2, Il-4, Il-5, Il-6, Il-8, Il-10, GM-CSF, TNF-α, and IFN-γ) and growth factors (G-CSF, FGF-2, EGF, and VEGF).Results: The time point of the peak level of pro-inflammatory cytokines was 7 weeks after start of treatment which corresponded for the majority of patients with termination of radiotherapy or chemoradiotherapy. Patients undergoing chemoradiotherapy exhibited a significant increase of IL-1β, IL-6, and IL-10 at 7 weeks as compared to pre-treatment levels. At 1 year after termination of treatment four patients experienced recurrence of disease while 26 patients were considered disease-free. The patients with recurrence had significantly higher levels of IL-1β, IL-6, IL-8, and IL-10 at 7 weeks after the start of treatment than patients without recurrence. Correlated with T stadium patients with T3-T4 had higher levels of IL-1β and IL-8 than patients with T1-T2 7 weeks after the start of treatment.Conclusions: The observed immune response in this explorative study demonstrates that chemoradiotherapy may induce not only a local treatment effect on the immune system but also effects far outside the irradiated field. The result of the study indicates that analysis of a pro-inflammatory panel of cytokines in serum at 7 weeks after the start of treatment could be of prognostic value in patients with head and neck cancer. Further study of a larger cohort could help identify patients at larger risk for recurrent disease with measurements of pro-inflammatory cytokines under and after treatment.

show abstract

Serum cytokine profile of laryngeal squamous cell carcinoma patients

Cited by 13 publications

References 34 publications

Expression Analysis of the Mediators of Epithelial to Mesenchymal Transition and Early Risk Assessment of Therapeutic Failure in Laryngeal Carcinoma

Expression Analysis of the Mediators of Epithelial to Mesenchymal Transition and Early Risk Assessment of Therapeutic Failure in Laryngeal Carcinoma

Comparing Cytokine Kinetics between Ranibizumab and Aflibercept in Central Retinal Vein Occlusion with Macular Edema

Systemic Inflammatory Reaction in Patients With Head and Neck Cancer—An Explorative Study

Contact Info

Product

Resources

About